Literature DB >> 23216436

An inhaled tumor necrosis factor-alpha-derived TIP peptide improves the pulmonary function in experimental lung injury.

E K Hartmann1, S Boehme, B Duenges, A Bentley, K U Klein, R Kwiecien, C Shi, M Szczyrba, M David, K Markstaller.   

Abstract

INTRODUCTION: The lectin-like domain of TNF-α enhances the fluid clearance across the alveolar barrier. For experimental purposes, the lectin-like domain can be mimicked by a synthetic peptide representing the TIP-motif of TNF-α. The present study aims to assess the acute effect of TIP on the pulmonary function in a porcine model of acute respiratory distress syndrome (ARDS).
METHODS: Lung injury was induced in 16 pigs (25-27 kg) by bronchoalveolar lavage followed by injurious ventilation. Following randomisation, either nebulised TIP (1 mg/kg; AP301, APEPTICO, Vienna, Austria) or water for injection (control group) was administered. During 5 h of monitoring, the extravascular lung water index (EVLWI), the quotient of partial pressure of oxygen and inspired oxygen concentration (PaO(2) /FiO(2) ) and the pulmonary shunt fraction were repetitively assessed. The data were evaluated by an analysis of variance including Bonferroni-Holm correction.
RESULTS: Comparable baseline conditions in both groups were achieved. Ventilatory parameters were standardised in both groups. In the TIP group, a significant reduction of the EVLWI and a simultaneous increase in the PaO(2) /FiO(2) ratio was shown (each P < 0.0001). No changes in the control group were observed (EVLWI: P = 0.43, PaO(2) /FiO(2) : P = 0.60). The intergroup comparison demonstrates a significant advantage of TIP inhalation over placebo (EVLWI: P < 0.0001, PaO(2) /FiO(2) : P = 0.004, shunt fraction: P = 0.0005).
CONCLUSIONS: The inhalation of TIP induces an amelioration of clinical surrogate parameters of the lung function in a porcine lung injury model. By mimicking the lectin-like domain, the synthetic TIP peptide AP301 is an innovative approach as supportive therapy in ARDS.
© 2012 The Acta Anaesthesiologica Scandinavica Foundation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23216436     DOI: 10.1111/aas.12034

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  20 in total

1.  A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation.

Authors:  István Czikora; Abdel Alli; Hui-Fang Bao; David Kaftan; Supriya Sridhar; Hans-Jürgen Apell; Boris Gorshkov; Richard White; Astrid Zimmermann; Albrecht Wendel; Meike Pauly-Evers; Jürg Hamacher; Irène Garcia-Gabay; Bernhard Fischer; Alexander Verin; Zsolt Bagi; Jean Francois Pittet; Waheed Shabbir; Rosa Lemmens-Gruber; Trinad Chakraborty; Ahmed Lazrak; Michael A Matthay; Douglas C Eaton; Rudolf Lucas
Journal:  Am J Respir Crit Care Med       Date:  2014-09-01       Impact factor: 21.405

Review 2.  Role of pancreatic fat in the outcomes of pancreatitis.

Authors:  Chathur Acharya; Sarah Navina; Vijay P Singh
Journal:  Pancreatology       Date:  2014-07-01       Impact factor: 3.996

Review 3.  Cytokine-Ion Channel Interactions in Pulmonary Inflammation.

Authors:  Jürg Hamacher; Yalda Hadizamani; Michèle Borgmann; Markus Mohaupt; Daniela Narcissa Männel; Ueli Moehrlen; Rudolf Lucas; Uz Stammberger
Journal:  Front Immunol       Date:  2018-01-04       Impact factor: 7.561

4.  Mechanism of action of novel lung edema therapeutic AP301 by activation of the epithelial sodium channel.

Authors:  Waheed Shabbir; Parastoo Scherbaum-Hazemi; Susan Tzotzos; Bernhard Fischer; Hendrik Fischer; Helmut Pietschmann; Rudolf Lucas; Rosa Lemmens-Gruber
Journal:  Mol Pharmacol       Date:  2013-09-27       Impact factor: 4.436

5.  The Acute Respiratory Distress Syndrome: Mechanisms and Perspective Therapeutic Approaches.

Authors:  J N Gonzales; R Lucas; A D Verin
Journal:  Austin J Vasc Med       Date:  2015-06-04

6.  A FIM study to assess safety and exposure of inhaled single doses of AP301-A specific ENaC channel activator for the treatment of acute lung injury.

Authors:  Richard Schwameis; Sandra Eder; Helmut Pietschmann; Bernhard Fischer; Hermann Mascher; Susan Tzotzos; Hendrik Fischer; Rudolf Lucas; Markus Zeitlinger; Robert Hermann
Journal:  J Clin Pharmacol       Date:  2014-03       Impact factor: 3.126

7.  TIP peptide inhalation in oleic acid-induced experimental lung injury: a post-hoc comparison.

Authors:  Erik K Hartmann; Alexander Bentley; Bastian Duenges; Klaus U Klein; Stefan Boehme; Klaus Markstaller; Matthias David
Journal:  BMC Res Notes       Date:  2013-09-27

8.  TIP peptide inhalation in experimental acute lung injury: effect of repetitive dosage and different synthetic variants.

Authors:  Erik K Hartmann; Rainer Thomas; Tanghua Liu; Joanna Stefaniak; Alexander Ziebart; Bastian Duenges; Daniel Eckle; Klaus Markstaller; Matthias David
Journal:  BMC Anesthesiol       Date:  2014-05-26       Impact factor: 2.217

9.  The effect of TIP on pneumovirus-induced pulmonary edema in mice.

Authors:  Elske van den Berg; Reinout A Bem; Albert P Bos; Rene Lutter; Job B M van Woensel
Journal:  PLoS One       Date:  2014-07-21       Impact factor: 3.240

10.  Inhalation therapy with the synthetic TIP-like peptide AP318 attenuates pulmonary inflammation in a porcine sepsis model.

Authors:  Erik K Hartmann; Alexander Ziebart; Rainer Thomas; Tanghua Liu; Arno Schad; Martha Tews; Bernd Moosmann; Jens Kamuf; Bastian Duenges; Serge C Thal; Matthias David
Journal:  BMC Pulm Med       Date:  2015-02-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.